FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US
FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US
An FDA study found that PRADAXA was associated with reduced risks of ischemic stroke, intracranial hemorrhage & death. View ISI, PI & Med Guide.